Illumina (ILMN) is trading down at $270.59 (-1.08%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Healthcare sector.
Illumina revenue & net income history (FY2016–FY2025)
| FY2016Jan 2017 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Jan 2021 | FY2021Jan 2022 | FY2022Jan 2023 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.40B | $2.75B | $3.33B | $3.54B | $3.24B | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B |
| Growth (year over year) | +8.0% | +14.8% | +21.1% | +6.3% | −8.6% | +39.7% | +1.3% | −1.7% | −2.9% | −0.7% |
| Gross profit | $1.67B | $1.83B | $2.30B | $2.47B | $2.20B | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B |
| Gross margin | 69.5% | 66.4% | 69.0% | 69.6% | 68.0% | 69.7% | 64.8% | 60.9% | 65.4% | 66.1% |
| Operating income | $587.0M | $606.0M | $883.0M | $985.0M | $580.0M | −$123.0M | −$4.18B | −$1.07B | −$833.0M | $807.0M |
| Operating margin | 24.5% | 22.0% | 26.5% | 27.8% | 17.9% | −2.7% | −91.2% | −23.7% | −19.1% | 18.6% |
| Net income | $463.0M | $726.0M | $826.0M | $1.00B | $656.0M | $762.0M | −$4.40B | −$1.16B | −$1.22B | $850.0M |
| Net margin | 19.3% | 26.4% | 24.8% | 28.3% | 20.3% | 16.8% | −96.1% | −25.8% | −28.0% | 19.6% |
| EPS (diluted) | $3.07 | $4.92 | $5.56 | $6.74 | $4.45 | $5.04 | −$28.00 | −$7.34 | −$7.69 | $5.45 |
| Balance sheet | ||||||||||
| Cash and equivalents | $735.0M | $1.23B | $1.14B | $2.04B | $1.81B | $1.23B | $2.01B | $1.05B | $1.13B | $1.42B |
| Total assets | $4.28B | $5.26B | $6.96B | $7.32B | $7.58B | $15.2B | $12.3B | $10.1B | $6.30B | $6.64B |
| Total liabilities | $2.01B | $2.51B | $3.11B | $2.70B | $2.89B | $4.48B | $5.65B | $4.37B | $3.93B | $3.92B |
| Long-term debt | $1.06B | $1.18B | $890.0M | $1.14B | $673.0M | — | — | — | — | — |
| Shareholders' equity | $2.20B | $2.75B | $3.76B | $4.61B | $4.69B | $10.7B | $6.60B | $5.75B | $2.37B | $2.72B |
| Cash flow | ||||||||||
| Operating cash flow | $779.0M | $875.0M | $1.14B | $1.05B | $1.08B | $545.0M | $392.0M | $478.0M | $837.0M | $1.08B |
| Capital expenditure | $260.0M | $310.0M | $296.0M | $209.0M | $189.0M | $208.0M | $286.0M | $195.0M | $128.0M | $148.0M |
| Free cash flow | $519.0M | $565.0M | $846.0M | $842.0M | $891.0M | $337.0M | $106.0M | $283.0M | $709.0M | $931.0M |
| Share buybacks | $249.0M | $251.0M | $201.0M | $324.0M | $736.0M | $0 | $0 | $0 | $116.0M | $742.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.08B | $1.10B | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B | $1.16B |
| Growth (year over year) | −3.5% | −1.6% | −3.3% | −4.8% | +0.4% | +5.0% | +4.8% | +9.4% |
| Gross profit | $745.0M | $728.0M | $683.0M | $695.0M | $733.0M | $759.0M | $721.0M | $770.0M |
| Gross margin | 69.0% | 65.9% | 65.6% | 65.6% | 67.6% | 65.5% | 66.1% | 66.4% |
| Operating income | $741.0M | $174.0M | $164.0M | $214.0M | $227.0M | $202.0M | $209.0M | $245.0M |
| Operating margin | 68.6% | 15.8% | 15.8% | 20.2% | 20.9% | 17.4% | 19.2% | 21.1% |
| Net income | $705.0M | $186.0M | $131.0M | $235.0M | $150.0M | $334.0M | $134.0M | $207.0M |
| Net margin | 65.3% | 16.8% | 12.6% | 22.2% | 13.8% | 28.8% | 12.3% | 17.9% |
| EPS (diluted) | $4.42 | $1.16 | $0.82 | $1.49 | $0.98 | $2.16 | $0.87 | $1.35 |
| Balance sheet | ||||||||
| Cash and equivalents | $869.0M | $1.13B | $1.11B | $934.0M | $1.05B | $1.42B | $1.09B | $1.04B |
| Total assets | $6.01B | $6.30B | $6.18B | $6.09B | $6.18B | $6.64B | $6.56B | $6.65B |
| Total liabilities | $3.89B | $3.93B | $3.81B | $3.83B | $3.80B | $3.92B | $3.88B | $3.81B |
| Shareholders' equity | $2.13B | $2.37B | $2.37B | $2.26B | $2.38B | $2.72B | $2.68B | $2.84B |
| Cash flow | ||||||||
| Operating cash flow | $316.0M | $364.0M | $240.0M | $234.0M | $284.0M | $321.0M | $289.0M | $201.0M |
| Capital expenditure | $32.0M | $29.0M | $32.0M | $30.0M | $31.0M | $55.0M | $38.0M | $40.0M |
| Free cash flow | $284.0M | $335.0M | $208.0M | $204.0M | $253.0M | $266.0M | $251.0M | $161.0M |
| Share buybacks | $99.0M | $17.0M | $200.0M | $370.0M | $130.0M | $42.0M | $242.0M | $128.0M |
From Illumina's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Illumina
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
Source: Wikipedia — Illumina, Inc.
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (1)
More Healthcare stocks
- HCA HCA Healthcare
- HSIC Henry Schein
- HUM Humana
- IDXX Idexx Laboratories
- INCY Incyte
- IQV IQVIA
- ISRG Intuitive Surgical
- JNJ Johnson & Johnson